- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05779475
An Observational Study of Patients With Moderate Parkinson's Disease (TRANSCEND 1)
January 17, 2024 updated by: Novo Nordisk A/S
The main purpose of this study is to follow and observe a group of people living with Parkinson's disease to see how study participation affects their signs and symptoms in the months after starting in the study.
While taking part in this study participants will take their usual medication as prescribed.
However, the study doctor may recommend adjustments to their medication to provide a better treatment of their Parkinson's disease.
Participation will last from 3 up to 24 months.
During visits to the clinic, the study doctor or study nurse will evaluate signs and symptoms of Parkinson's disease using several different assessments.
At a minimum of 2 visits participants will be asked to undergo 'off'-assessments.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
96
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shinjuku-ku, Tokyo, Japan, 160-8582
- Keio University Hospital
-
-
-
-
-
Lund, Sweden, 222 42
- Neurologimottagningen Lund
-
-
-
-
-
Cambridge, United Kingdom, CB2 0PY
- Clinical Neuroscience
-
-
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
New York, New York, United States, 10021
- NY Presbyt Hosp-W Cornell Med
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Participants with Parkinson's disease will be included.
The participants will not receive any investigational treatment in this study.
Description
Inclusion Criteria:
- Male or female, aged 50-68 years (both inclusive) at the time of signing informed consent.
- Diagnosed with Parkinson's disease using the Movement Disorder Society (MDS) criteria (fulfilling the definition of clinically probable Parkinson's disease).
- Moderate Parkinson's disease, e.g. as defined by i) modified Hoehn and Yahr stage 2-3 in OFF state and ii) MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III total score greater than or equal to (≥) 30 in OFF state, both as judged by the investigator.
- Patient has symptoms that are not adequately controlled by existing oral anti-Parkinson's disease medications, i.e., having both ON and OFF periods, as judged by the investigator.
- Parkinson's disease duration greater than (>) 5 years and lesser than or equal to (≤) 12 years from diagnosis at the time of signing informed consent.
- Potential candidate for a future cell therapy transplantation, as judged by the investigator.
- Life expectancy >7 years as judged by the investigator.
Exclusion Criteria:
- Any atypical or secondary Parkinson's disease, or non-Parkinson's disease-suspected cause(s) of, or contributors to, parkinsonism, as judged by the investigator.
- Significant drug-induced dyskinesias as judged by the investigator, e.g., as defined by a score of > 2 in the Abnormal Involuntary Movement Scale (AIMS), in any body part in the ON state.
- Tremor-dominant Parkinson's disease, as judged by the investigator.
- Cognitive impairment predictive of dementia (including Parkinson's disease dementia) or other cognitive dysfunction as judged by the investigator, e.g., as defined by Montreal Cognitive Assessment (MoCA) score ≤ 24, or evidence of major neurocognitive disorder according to the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) criteria.
- Major medical or psychiatric disorder (e.g., depression (Montgomery-Asberg Depression Rating Scale (MADRS) >20) or psychosis), or other disease making the patient unsuited for participation in the study, as judged by the investigator.
- Treatment for dystonia or spasticity within 3 months of screening (Botox for a focal dystonia is allowed).
- Substantial neurological symptoms not accounted for by Parkinson's disease, including active seizure disorder, as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with Parkinson's disease
Participants will not receive any investigational treatment in this study.
The participants will be treated with anti-Parkinson's disease medication according to local standard of care.
|
Participants will not receive any investigational treatment in this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (motor score) in OFF state
Time Frame: From baseline (week 0) to end of study (13 to 104 weeks from baseline)
|
Measured as score.
MDS-UPDRS consists of 4 parts - has 65 items/questions in total.
Part III assesses the motor function of the patient at the time of the visit conducted in both the OFF and ON state.
Each item will receive a score ranging from 0 to 4, where 0 represents the absence of impairment and 4 represents the highest degree of impairment.
|
From baseline (week 0) to end of study (13 to 104 weeks from baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in MDS-UPDRS Part III (motor score) in OFF state
Time Frame: From last medication adjustment (between week 0 and week 104) to end of study (13 to 104 weeks from baseline)
|
Measured as score.
MDS-UPDRS consists of 4 parts - has 65 items/questions in total.
Part III assesses the motor function of the patient at the time of the visit conducted in both the OFF and ON state.
Each item will receive a score ranging from 0 to 4, where 0 represents the absence of impairment and 4 represents the highest degree of impairment.
|
From last medication adjustment (between week 0 and week 104) to end of study (13 to 104 weeks from baseline)
|
Is the patient interested in being considered for participation in a cell therapy transplantation study (yes/no)
Time Frame: At end of study (13 to 104 weeks from baseline)
|
Measured as count of participants
|
At end of study (13 to 104 weeks from baseline)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 5, 2023
Primary Completion (Estimated)
October 22, 2025
Study Completion (Estimated)
October 22, 2025
Study Registration Dates
First Submitted
March 9, 2023
First Submitted That Met QC Criteria
March 9, 2023
First Posted (Actual)
March 22, 2023
Study Record Updates
Last Update Posted (Estimated)
January 18, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9001-4704
- U1111-1254-1741 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on No treatment given
-
Robert G. Grossman, MDThe University of Texas Health Science Center, Houston; University of Maryland... and other collaboratorsRecruitingSpinal Cord InjuryUnited States, Canada
-
Novo Nordisk A/SEnrolling by invitationSystemic Inflammation | Chronic Kidney Disease (CKD) | Atherosclerotic Cardiovascular Disease (ASCVD)United States
-
Novo Nordisk A/SEnrolling by invitationHeart Failure | Chronic Kidney Disease | Cardiovascular RiskKorea, Republic of, China, United States, Argentina, Germany, Canada, Poland, Brazil
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedNon-alcoholic Steatohepatitis (MASH) | Non-alcoholic Fatty Liver Disease (MASLD)India
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedType 2 DiabetesKorea, Republic of, Mexico, India, United Kingdom, Australia, France, Saudi Arabia
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare ProfessionalsSpain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1India